National Heart, Lung, and Blood Institute. Vital statistics of the United States. Rockville, MD: National Center for Health Statistics, 1986.
2.
Working Group on Arteriosclerosis of the National Heart, Lung, and Blood Institute. Report of the Working Group on Arteriosclerosis of the National Heart, Lung and Blood Institute-summary, conclusions, and recommendations. Vol 1. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH publication no 81-2034, June1981.
3.
Working Group on Arteriosclerosis of the National Heart, Lung, and Blood Institute. Report of the Working Group on Arteriosclerosis of the National Heart, Lung, and Blood Institute. Vol 2, Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH publication no 81-2035, Sept1981.
4.
RidkerPM, CushmanM, StampferMJ, TracyRP, HennekensCH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997;31(5):337–56.
5.
RanwsEA, TytgatGN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet1990;35(8700):1233–5.
6.
GraystonIT, KuoC-C, CampbellLA, WangS-P. Chlamydia pneumoniae sp. Nov. for Chlamydia sp strain TWAR. Int J Syst Bacteriol1989;39:88–90.
7.
GraystonIT, CampbellLA, KuoC-C, A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis1990;161:618–25.
8.
SaikkuP, MattilaK, NieminenMS, Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet1988;2(8618):983–6.
SaikkuP, LeinonenM, TenkanenL, Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med1992;116:273–8.
11.
LinnanmakiE, LeinonenM, MattilaK, Chlamydia pneumoniae specific circulating immune complexes in patients with chronic coronary heart disease. Circulation1993;87:1130–4.
12.
ThomDH, GraystonJI, SiscovickDS, WangS-P, WeissNS, DalingJR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA1992;268:68–72.
MelnickSL, ShaharE, FolsomAR, Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med1993;95:449–504.
15.
PuolakkainenM, KuoC-C, ShorA, Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol1993;31:2212–4.
16.
ShorA, KuoCC, PattonDL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J1992;82:158–61.
17.
MuhlesteinJB, HammondEH, CarlquistJF, Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol1996;27:1555–61.
18.
KuoC-C, ShorA, CampbellLA, Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis1993;167:841–9.
19.
GraystonJT, KuoCC, CoulsonAS, Chlamydia pneumoniae (TWAR) in atherosclersosis of the carotid artery, Circulation1995;92(12):3397–400.
20.
KuoC-C, GownAM, BendittEP, GraystonJT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb1993;13:1501–4.
21.
KuoC-C, GraystonJT, CampbellLA, Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proceed National Acad Sci, USA1995;92:6811–6914.
22.
DavidsonM, KuoCC, MiddaughJP, CampbellLA, WangSP, NewmanWP, FinleyJC, GraystonJT. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation1998;98:628–33.
23.
MoxonER. Microbes, molecules, and man. The Mitchell lecture. J R Coll Physicians London1993;27(2):169–74.
24.
FongIW, ChiuB, ViiraE, FongMW, JangD, MahonyJ.Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol1997;35(1):48–52.
25.
MuhlesteinJB, AndersonJL, HammondEH, ZhaoL, TrehanS, SchwobeEP, CarlquistJF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation1998;97:633–6.
26.
GuptaS, LeathamEW, CarringtonD, MendallMA, KaskiJC. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation1997;96(2):404–7.
27.
GurfinkelE, BozovichG, DarocaA, BeckE, MautnerB; ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet1997;350(9075):404–7.
28.
MendallMA, GogginPM, MolineauxN, LevyJ, ToosyT, StrachanD, CammAJ, NorthfieldTC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J1994;71(5):437–9.
29.
DaneshJ, CollinsR, PetoR.Chronic infections and coronary heart disease: is there a link?Lancet1997;350(9075):430–6.
30.
DaneshJ, PetoR.Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ1998;316(7138):1130–2.
